The Centers for Medicare and Medicaid Services (CMS) is the U.S. federal agency, within the Department of Health and Human Services, that administers Medicare, Medicaid, and related programs. As the largest single payer in U.S. health care, CMS shapes how artificial intelligence is adopted in the sector both through its own payment and review models and through the incentives its coverage decisions create for vendors and providers. Its activity connects to Healthcare — AI Deployment and to the FDA's parallel role over AI medical devices (FDA — Food and Drug Administration (AI Deployer)).
AI-related payment and review models
ACCESS payment model. CMS launched ACCESS, an outcome-based payment model, with 150 health-AI companies in its first pilot, requiring vendors to demonstrate measurable patient impact rather than running demonstrations for hospitals (announced May 13, 2026). The 10-year program is scheduled to go live July 5, 2026 and is described as the first Medicare mechanism to pay for AI agents that monitor patients between visits (Source: techcrunch.com).
WISeR Model. CMS's Innovation Center created the Wasteful and Inappropriate Services Reduction (WISeR) Model to test whether enhanced technologies, including AI, can speed prior-authorization decisions in Original (Traditional) Medicare. The model is a six-year test, structured in two three-year agreement periods, beginning January 1, 2026, initially operating in a set of states including Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington (Source: cms.gov). The model has drawn scrutiny from members of Congress and patient advocates concerned about AI-assisted denial of care in Traditional Medicare, where prior authorization has historically been limited.
Policy positions on clinical autonomy
The appropriate degree of clinical autonomy for AI has emerged as a point of disagreement between CMS and parts of the medical profession. On June 22, 2026, CMS Administrator Mehmet Oz urged the American Medical Association to be open to autonomous and semiautonomous AI in health care, while AMA CEO John Whyte countered that AI should support rather than replace clinician decision-making and needs new guardrails (Source: insideaipolicy.com). The exchange tracks the support-not-replace framing reflected in the AMA's own survey data (AMA Physician AI Sentiment Report (2026)) and in the patient-outcomes evidence debate associated with Eric Topol and Gary Marcus, who locate the strongest evidence for AI value in administrative workflows such as prior authorization, claims appeals, and coding rather than clinical decision-making.
Relationships
- deploys-in: Healthcare — AI Deployment
- related: FDA — Food and Drug Administration (AI Deployer) (parallel federal role over AI medical devices)
- related: Eric Topol, Gary Marcus (administrative-vs-clinical evidence framing)
- regulated-by: n/a (CMS is itself a payer/administrator and deployer)
Sources
- CMS / CMS Launches New Model to Target Wasteful, Inappropriate Services in Original Medicare (WISeR): cms.gov
- Inside AI Policy / CMS' Oz, AMA at odds over autonomous AI (June 22, 2026): insideaipolicy.com
- TechCrunch / Medicare's new payment model is built for AI, and most of the tech world has no idea (May 12, 2026): techcrunch.com